

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYOBBEND Page 1 of 3

DOCTOR'S ORDERS Ht	cm	Wtk	g BSA_	m²	
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form					
DATE: To be giv	en:	С	ycle #:		
Date of Previous Cycle:					
☐ Delay treatment week(s) ☐ CBC & Diff and platelets day 1 of treatment Day 1: may proceed with doses as written, if within greater than or equal to 80 x 10 ⁹ /L Proceed with treatment based on blood work from		eater than or equ	ual to 1.2	x 10 ⁹ /L and Platelets	
PREMEDICATIONS: Patient to take own supply	RN/Pharmacist	to confirm		·	
PREMEDICATIONS FOR OBINUTUZUMAB INFUSION: Cycle 1: Day 1 60 minutes prior to infusion, repeat in 4 hours if infusion exceeds 4 hours: dexamethasone 20 mg IV in 50 mL NS over 15 minutes 30 minutes prior to infusion, repeat in 4 hours if infusion exceeds 4 hours: acetaminophen					
** Have Hypersensitivity Reaction Tray and Protocol Available**					
DOCTOR'S SIGNATURE:				SIGNATURE: UC:	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYOBBEND Page 2 of 3

PREMEDICATIONS FOR OBINUTUZUMAB MONOTHERAPY Cycle 7 to 18: Day 1 (monotherapy with oBiNutuzumab) 30 minutes prior to infusion, repeat in 4 hours if infusion exceeds 4 hours: acctaminophen	Date:				
Cycle 7 to 18: Day 1 (monotherapy with oBINutuzumab) 30 minutes prior to infusion, repeat in 4 hours if infusion exceeds 4 hours: acctaminophe					
30 minutes prior to infusion, repeat in 4 hours if infusion exceeds 4 hours: acetaminophen	PREMEDICATIONS FOR OBINUTUZUMAB MONOTHERAPY				
acetaminophen	Cycle 7 to 18: Day 1 (monotherapy with oBINutuzumab)				
TREATMENT: INDUCTION PHASE: Cycle 1 to 6 Cycle 1: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. Start infusion at 50 mg/h; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 2 hours post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) Day 8 and 15: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Cycles 2 to 6: Day 1: OBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3					
Induction PHASE: Cycle 1 to 6 Cycle 1: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. Start infusion at 50 mg/h; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 2 hours post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) Day 8 and 15: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Cycles 2 to 6: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3	diphenhydrAMINE 50 mg PO				
□ Cycle 1: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. Start infusion at 50 mg/h; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 2 hours post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) Day 8 and 15: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction □ Cycles 2 to 6: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3	TREATMENT:				
Day 1: oBINtutzumab 1000 mg IV in 250 mL NS. Start infusion at 50 mg/h; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 2 hours post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) Day 8 and 15: oBINutzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Cycles 2 to 6: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3	INDUCTION PHASE: Cycle 1 to 6				
oBiNutuzumab 1000 mg IV in 250 mL NS. Start infusion at 50 mg/h; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 2 hours post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) Day 8 and 15: oBiNutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Cycles 2 to 6: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3	☐ Cycle 1:				
Pays 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) Day 8 and 15: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Cycles 2 to 6: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3	oBlNutuzumab 1000 mg IV in 250 mL NS. Start infusion at 50 mg/h; after 30 minutes, increase by 50 mg/h every 30				
bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) Day 8 and 15: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Cycles 2 to 6: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3					
IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) Day 8 and 15: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Cycles 2 to 6: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3	Days 1 and 2:				
Day 8 and 15: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Cycles 2 to 6: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3	bendamustine 90 mg/m² x BSA = mg				
oBlNutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Cycles 2 to 6: Day 1: oBlNutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3	IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion)				
Refer to protocol for resuming infusion following a reaction Cycles 2 to 6: Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3	oBÍNutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in				
Day 1: oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3					
 oBiNutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3 	☐ Cycles 2 to 6:				
Refer to protocol for resuming infusion following a reaction Days 1 and 2: bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3	oBINutuzumab 1000 mg IV in 250 mL NS. If no infusion reaction or only grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h . Increase by 100 mg/h every 30 minutes until rate = 400 mg/h				
bendamustine 90 mg/m² x BSA = mg IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3					
IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion) See page 3	Days 1 and 2:				
See page 3	bendamustine 90 mg/m² x BSA = mg				
See page 3	IV in 250 to 500 mL NS over 1 hour. (Day 1 treatment to be administered after obinutuzumab infusion)				
	See page 3				
	DOCTOR'S SIGNATURE:	SIGNATURE:			
UC:		UC:			



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYOBBEND Page 3 of 3

Date:				
TREATMENT: (Continued)				
MAINTENANCE PHASE				
☐ Cycle 7 to 18: Day 1				
oBINutuzumab 1000 mg IV in 250 mL NS on Day 1 . If no infusion reaction or only grade 1 infusion reaction only in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h . Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs.				
Vital signs prior to start of infusion and at every increment of infusion rate and for 30 minutes post infusion Refer to protocol for resuming infusion following a reaction	1			
RETURN APPOINTMENT ORDERS				
☐ Cycle 1: Return in four weeks for Doctor and Cycle Book chemo on days 1, 2, 8 and 15.				
Cycle 2 to 6: Return in four weeks for Doctor and Cycle Book chemo on days 1 and 2.				
Cycle 7 to 18: Return in <u>eight</u> weeks for Doctor and Cycle Book chemo on day 1.				
Last Cycle. Return in week(s).				
CBC & Diff, platelets prior to Day 1 of each cycle				
☐ If clinically indicated: ☐ creatinine ☐ ALT ☐ bilirubin				
☐ Other tests:				
☐ Consults:				
☐ See general orders sheet for additional requests.				
DOCTOR'S SIGNATURE:	SIGNATURE:			
	UC:			